Carregant...
High Dose Erythropoietin in ELGANs does not Alter Risk of Retinopathy of Prematurity
INTRODUCTION: The Preterm Erythropoietin (Epo) Neuroprotection (PENUT) Trial sought to determine the safety and efficacy of early high-dose Epo as a potential neuroprotective treatment. We hypothesized that Epo would not increase the incidence or severity of retinopathy of prematurity (ROP). METHODS...
Guardat en:
| Publicat a: | Neonatology |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7855231/ https://ncbi.nlm.nih.gov/pubmed/33113526 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000511262 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|